<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02853370</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG 36</org_study_id>
    <nct_id>NCT02853370</nct_id>
  </id_info>
  <brief_title>Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma</brief_title>
  <official_title>Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <brief_summary>
    <textblock>
      Splenic Marginal Zone Lymphoma (SMZL) is a well-defined low-grade B-cell lymphoma,considered&#xD;
      as a rare neoplasm accounting for about 2% of all non-Hodgkin's lymphomas (NHL) and&#xD;
      represents for most cases of otherwise unclassifiable chronic lymphoid B-cell cluster of&#xD;
      differentiation antigen 5 (CD5)-lymphoproliferative disorders. SMZL is characterized by an&#xD;
      almost exclusive involvement of the spleen and bone marrow and in about 25% of cases the&#xD;
      disease pursues an aggressive course and most patients die of lymphoma progression within 3-4&#xD;
      years.&#xD;
&#xD;
      Retrospective studies have indicated that purine analogous achieved very high response rates&#xD;
      in both naïve and pre-treated patients. Moreover, the introduction of the anti-cluster of&#xD;
      differentiation antigen 20 (CD20) humanized antibody rituximab, either used alone or in&#xD;
      combination with chemotherapy has been reported to be very effective in producing a rapid&#xD;
      clearance of neoplastic cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicenter, open-label, phase II study, designed to determine efficacy and&#xD;
      safety of a Chemo-immunotherapy with the combination of bendamustine + rituximab in patients&#xD;
      with splenic marginal zone lymphoma.&#xD;
&#xD;
      Study Population: previously untreated (except for splenectomy and/or antiviral therapy for&#xD;
      Hepatitis C Virus (HCV) infection) and symptomatic Splenic Marginal Zone patients.&#xD;
&#xD;
      Objectives: evaluation of the efficacy and the safety of R-Bendamustine in symptomatic&#xD;
      Splenic Marginal Zone Lymphoma patients.&#xD;
&#xD;
      Primary Objective: efficacy of R-Bendamustine measured by Complete Response rate. Complete&#xD;
      response rate defined as regression to normal size on CT of organomegaly (spleen, liver,&#xD;
      lymph nodes); normalization of the blood counts and no evidence of circulating clonal cells,&#xD;
      and no evidence or minor (≤ 5%) Bone Marrow (BM) infiltration detected by&#xD;
      immunohistochemistry (IHC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CT-scan of organomegaly (spleen-liver-lymph nodes)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Marginal Zone B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bendamustine and Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Phase (Cycle 1 to Cycle 3 ):&#xD;
Bendamustine 90 mg/sqm i.v. d1 &amp; d2* Rituximab 375 mg/m2 i.v. d1**&#xD;
Extended Phase (Cycle 4 to Cycle 6):&#xD;
Bendamustine 90 mg/sqm i.v. d1 &amp; d2* Rituximab 375 mg/m2 i.v. d1&#xD;
From Cycle 4 to Cycle 6, every 4 weeks, depending on the response after the first 3 Cycles&#xD;
*Or days 2-3 according to institutional/patient/physician preference&#xD;
**Administration of Rituximab during cycle 1 and cycle 2 can be postponed to day 8 or 14 in case of risk of tumor lysis syndrome (TLS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine and Rituximab</intervention_name>
    <arm_group_label>Bendamustine and Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Initial diagnosis of CD20+ Splenic Marginal Zone Lymphoma morphology confirmed by&#xD;
             histology, cytology, immunophenotype (chromosomal abnormalities by quantitative&#xD;
             multiplex Polymerase Chain Reaction (PCR) of short fluorescent fragments (QMPSF) is&#xD;
             optional) according to World Health Organization (WHO) 2008 classification of Lymphoma&#xD;
             criteria or according to the recommendation of the Splenic Lymphoma Group for non&#xD;
             splenectomized patient.&#xD;
&#xD;
               1. If patients not splenectomised: diagnosis on bone marrow biopsy (histology and&#xD;
                  immunohistochemistry), and blood (cytology, immunophenotype), chromosomal&#xD;
                  abnormalities by QMPSF optional.&#xD;
&#xD;
               2. If patients splenectomised diagnosis on spleen, bone marrow biopsy (histology and&#xD;
                  immunohistochemistry), and blood (cytology, immunophenotype) chromosomal&#xD;
                  abnormalities by QMPSF optional.&#xD;
&#xD;
          -  No previous treatment with immunotherapy or chemotherapy or radiotherapy unless&#xD;
             pretreatment by mono corticotherapy.&#xD;
&#xD;
          -  Patients requiring a treatment with at least one of the following situation:&#xD;
&#xD;
               1. Symptomatic SMZL in not splenectomized patients&#xD;
&#xD;
                    1. Bulky (arbitrarily defined as ≥6 cm below left costal margin) or progressive&#xD;
                       or painful splenomegaly, without enlarged lymphoadenopathy, with or without&#xD;
                       cytopenia, not eligible for splenectomy or not willing splenectomy&#xD;
&#xD;
                    2. One of the following symptomatic/progressive cytopenias: Hb &lt;10 g/dL, or&#xD;
                       Plat &lt;80.000/mm3, or ANC &lt;1.000/mm3, whatever the reason (autoimmune or&#xD;
                       hypersplenism or bone marrow infiltration) not eligible for splenectomy or&#xD;
                       not willing splenectomy&#xD;
&#xD;
                    3. SMZL with enlarged lymphoadenopathy or involvement of extranodal sites with&#xD;
                       or without cytopenia&#xD;
&#xD;
               2. Symptomatic disease in SMZL splenectomised patients with rapidly raising&#xD;
                  lymphocyte counts, development of lymphadenopathy or involvement of extranodal&#xD;
                  sites.&#xD;
&#xD;
               3. SMZL with concomitant hepatitis C infection who have not responded or are&#xD;
                  relapsed after Interferon and/or Ribavirin.&#xD;
&#xD;
          -  Clinically and/or radiologically confirmed measurable disease before treatment start.&#xD;
&#xD;
          -  Aged ≥ 18 yo at time of initial diagnosis and ≤ 80 yo.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Minimum life expectancy of &gt;6 months.&#xD;
&#xD;
          -  Voluntary signed informed consent before performance of any study related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the patient at any time without prejudice to future medical care.&#xD;
&#xD;
          -  The following laboratory values at screening:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.000/mm3 and Platelets ≥100.000/mm3, unless&#xD;
                  these abnormalities are related to bone marrow infiltration or to hypersplenism.&#xD;
&#xD;
               2. Aspartate transaminase (AST) ≤2 x upper limit of normal (ULN); Alanine&#xD;
                  transaminase (ALT) ≤2 x ULN; total bilirubin ≤1.5 x ULN.&#xD;
&#xD;
               3. Creatinine clearance ≥ 10 ml/min (as calculated by the Cockcroft-Gault formula)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as defined by the investigator.&#xD;
&#xD;
          -  Active systemic infection requiring treatment.&#xD;
&#xD;
          -  Previously known HIV positive serology.&#xD;
&#xD;
          -  Active hepatitis B virus infection (presence of antigen hepatitis B surface (HBS)+; in&#xD;
             case of presence of antibody anti hepatitis B core antigen (HBC)+ and anti HBS+,&#xD;
             controls should be organized according to guidelines of American Association for the&#xD;
             Study of Liver Disease (AASLD) and European Association for the Study of the Liver&#xD;
             (EASL)).&#xD;
&#xD;
          -  Active and previously untreated HCV infection.&#xD;
&#xD;
          -  Prior history of malignancies other than lymphoma within 3 years (except for complete&#xD;
             resection of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ&#xD;
             malignancy). Patients previously diagnosed with prostate cancer are eligible if (1)&#xD;
             their disease was T1-T2a, N0, M0, with a Gleason score ≤7, and a prostate specific&#xD;
             antigen (PSA) ≤10 ng/mL prior to initial therapy, (2) they had definitive curative&#xD;
             therapy (ie, prostatectomy or radiotherapy) ≥2 years before Day 1 of Cycle 1, and (3)&#xD;
             at a minimum 2 years following therapy they had no clinical evidence of prostate&#xD;
             cancer, and their Prostate Specific Antigen(PSA) was undetectable if they underwent&#xD;
             prostatectomy or &lt;1 ng/mL if they did not undergo prostatectomy.&#xD;
&#xD;
          -  Major surgery within 30 days before the inclusion in the study&#xD;
&#xD;
          -  A positive Coombs test without haemolysis or an autoimmune hemolytic anemia is not an&#xD;
             exclusion criterion.&#xD;
&#xD;
          -  Impaired renal function with creatinine clearance &lt;10 ml/min.&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease with hypoxemia.&#xD;
&#xD;
          -  Medical condition requiring long-term use (&gt;1 month) of systemic corticosteroids.&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
          -  Prior participation in another study with experimental drug during the last 4 months.&#xD;
&#xD;
          -  Pregnant or currently breast-feeding woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilio Iannitto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Presidio ospedaliero G. Moscati; UOC di Ematologia - Taranto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Créteil (Hôpital Henri Mondor)</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dijon (CHU de Dijon - Hôpital d'Enfants)</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble cedex 9 (CHU Michallon)</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Kremlin Bicêtre (Hôpital Bicêtre)</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Mans (C.H. Le Mans)</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille cedex (CHRU Lille - Hôpital Claude Huriez)</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Bénite</name>
      <address>
        <city>Lyon Sud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vandoeuvre-les-Nancy cedex (CHU Brabois)</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes cedex 01 (CHU de Nantes - Hôtel Dieu)</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris cedex 10 (Hôpital Saint-Louis)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pessac cedex (Centre François Magendie)</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen (Centre Henri Becquerel)</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Ss. Antonio E Biagio</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Armando Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Martino Di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori - Sede Di Meldola (Fc)</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Fondazione Centro S. Raffaele Del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. &quot;V. Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Giaccone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria Delle Croci Di Di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bianchi - Melacrino - Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Di S. Maria Nuova-Irccs</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Centro Di Riferimento Oncologico Di Basilicata (Crob)</name>
      <address>
        <city>Rionero</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Dermatologico S. Gallicano (Ifo)</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S. Maria&quot;</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Circolo E Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

